Traws Pharma, Inc. (NASDAQ:TRAW) to Post Q3 2024 Earnings of ($0.25) Per Share, Noble Financial Forecasts

Traws Pharma, Inc. (NASDAQ:TRAW) – Stock analysts at Noble Financial issued their Q3 2024 earnings per share (EPS) estimates for Traws Pharma in a research report issued to clients and investors on Friday, August 16th. Noble Financial analyst R. Leboyer forecasts that the company will earn ($0.25) per share for the quarter. Noble Financial also issued estimates for Traws Pharma’s Q4 2024 earnings at ($0.28) EPS, Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.36) EPS and FY2025 earnings at ($1.35) EPS.

Traws Pharma Trading Down 6.5 %

Shares of Traws Pharma stock opened at $0.36 on Monday. Traws Pharma has a 12-month low of $0.33 and a 12-month high of $1.10. The stock has a market cap of $9.11 million, a P/E ratio of -0.41 and a beta of 1.37. The firm’s fifty day moving average is $0.42.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.